On April 11, 2016 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, reported that Curis scientists and its collaborator, Aurigene will present data from multiple programs at the Annual Meeting of American Association of Cancer Research (AACR) (Free AACR Whitepaper) to be held from April 16 – 20, 2016 in New Orleans, LA (Press release, Curis, APR 11, 2016, View Source [SID:1234510647]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Curis researchers will present data for its proprietary targeted cancer drug candidate, CUDC-907, an oral inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K). Curis’ collaborator, Aurigene will present data from the immuno-oncology programs, including CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), as well as the PD-L1/ T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) antagonist program. In addition, Aurigene will present data from the interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor program, including the lead compound CA-4948. Curis has exclusive licenses to CA-170 and CA-4948 under a collaboration agreement with Aurigene established in 2015.

Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.

Poster Presentations

Date/Time: Wednesday, Apr 20, 2016, 8:00 AM – 12:00 PM
Session Title: Cellular Responses to Anticancer Drugs
Presentation Title: Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies
Abstract Number: 4634

Date/Time: Wednesday, Apr 20, 2016, 8:00 AM – 12:00 PM
Session Title: Immune Modulating Agents 2
Presentation Title: Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy
Abstract Number: 4861

Date/Time: Wednesday, Apr 20, 2016, 8:00 AM – 12:00 PM
Session Title: Novel Chemotherapies
Presentation Title: Efficacy and safety of highly selective novel IRAK4 inhibitors for treatment of ABC-DLBCL
Abstract Number: 4798